Hemogenyx Pharmaceuticals plc (HEMO) Reports H1 Loss £6.56M, Cash £4.58M

Hemogenyx Pharmaceuticals plc reported an unaudited H1 2026 loss before tax of £6.56M on operating costs of £6.48M, and cash of £4.58M. The company raised £5.6M during H1 and plans adult dose escalation and a pediatric arm for HG-CT-1.Material DetailsContext by AI AnalystThis is an early-stage clin…